NVS - Enliven Therapeutics Well-Positioned With Conservative Trading Levels-Analyst Says | Benzinga
Mizuho Securities initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN), a clinical-stage precision oncology company focused on discovering and developing next-generation small molecule kinase inhibitors.
The company’s lead product, ELVN-001, is under development for Chronic myelogenous leukemia (CML), a slow-progressing blood cancer that begins in the bone marrow.
Thursday, Enliven Therapeutics will host a webcast to discuss initial proof of concept data on ELVN-001.
Additional Phase 1 data is expected in 2025, but Mizuho expects late 2024 could also be possible.
Mizuho writes that the CML tyrosine kinase inhibitors (TKI) market is established, ~$13 billion-$14 ...